Risk factor
Very vulnerable to price shocks
Profitability factor
Greatly overvalued vs peers
About
Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to...
Company Valuation
From both historical and forecast perspectives, the stock is considerably overpriced compared to similar stocks. In particular, the stock is overvalued on P/FCF.
Target Price
The average target price of NTRA is 276 and suggests 45% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increas
Buy
Sell